Skip to main content
Erschienen in: Breast Cancer Research 2/2011

01.04.2011 | Viewpoint

More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response

verfasst von: Xiaoyong Fu, Catherine Huang, Rachel Schiff

Erschienen in: Breast Cancer Research | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Estrogen receptor α (ER) is a major driver of breast cancer and the target of endocrine therapy. Full disclosure of the cofactors regulating ER interactions with chromatin and its transcriptional regulatory activity is still elusive. Novel genome-wide profiling tools have mapped ER binding events in breast cancer cells and delineated cofactors important in ER activity. Among these, the Forkhead protein FOXA1 is emerging as a key factor dictating global chromatin structure and the transcriptional function of ER in breast and non-breast cancer cells. The significance of FOXA1 in the chromatin interactions and transcriptional regulation of both estrogen- and tamoxifen-bound ER, and in supporting tamoxifen-resistant cell growth, may impact current endocrine therapies.
Literatur
1.
2.
Zurück zum Zitat Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M: Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006, 38: 1289-1297. 10.1038/ng1901.CrossRefPubMed Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M: Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006, 38: 1289-1297. 10.1038/ng1901.CrossRefPubMed
3.
Zurück zum Zitat Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L, Pan YF, Li G, Lim M, Thomsen JS, Ruan Y, Clarke ND, Prabhakar S, Cheung E, Liu ET: Integrative model of genomic factors for determining binding site selection by estrogen receptor-alpha. Mol Syst Biol. 2010, 6: 456-10.1038/msb.2010.109.CrossRefPubMedPubMedCentral Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L, Pan YF, Li G, Lim M, Thomsen JS, Ruan Y, Clarke ND, Prabhakar S, Cheung E, Liu ET: Integrative model of genomic factors for determining binding site selection by estrogen receptor-alpha. Mol Syst Biol. 2010, 6: 456-10.1038/msb.2010.109.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA. 2005, 102: 11651-11656. 10.1073/pnas.0505575102.CrossRefPubMedPubMedCentral Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA. 2005, 102: 11651-11656. 10.1073/pnas.0505575102.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H: FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res. 2007, 13: 4415-4421. 10.1158/1078-0432.CCR-07-0122.CrossRefPubMed Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H: FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res. 2007, 13: 4415-4421. 10.1158/1078-0432.CCR-07-0122.CrossRefPubMed
6.
Zurück zum Zitat Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS: Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 2002, 9: 279-289. 10.1016/S1097-2765(02)00459-8.CrossRefPubMed Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS: Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 2002, 9: 279-289. 10.1016/S1097-2765(02)00459-8.CrossRefPubMed
7.
Zurück zum Zitat Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2010, 43: 27-33. 10.1038/ng.730.CrossRefPubMedPubMedCentral Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2010, 43: 27-33. 10.1038/ng.730.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG: ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J. 2009, 28: 1418-1428. 10.1038/emboj.2009.88.CrossRefPubMedPubMedCentral Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG: ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J. 2009, 28: 1418-1428. 10.1038/emboj.2009.88.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Gu F, Hsu HK, Hsu PY, Wu J, Ma Y, Parvin J, Huang TH, Jin VX: Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data. BMC Syst Biol. 2010, 4: 170-10.1186/1752-0509-4-170.CrossRefPubMedPubMedCentral Gu F, Hsu HK, Hsu PY, Wu J, Ma Y, Parvin J, Huang TH, Jin VX: Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data. BMC Syst Biol. 2010, 4: 170-10.1186/1752-0509-4-170.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Lupien M, Eeckhoute J, Meyer CA, Krum SA, Rhodes DR, Liu XS, Brown M: Coactivator function defines the active estrogen receptor alpha cistrome. Mol Cell Biol. 2009, 29: 3413-3423. 10.1128/MCB.00020-09.CrossRefPubMedPubMedCentral Lupien M, Eeckhoute J, Meyer CA, Krum SA, Rhodes DR, Liu XS, Brown M: Coactivator function defines the active estrogen receptor alpha cistrome. Mol Cell Biol. 2009, 29: 3413-3423. 10.1128/MCB.00020-09.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M: Growth factor stimulation induces a distinct ER (alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev. 2010, 24: 2219-2227. 10.1101/gad.1944810.CrossRefPubMedPubMedCentral Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M: Growth factor stimulation induces a distinct ER (alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev. 2010, 24: 2219-2227. 10.1101/gad.1944810.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Bhat-Nakshatri P, Wang G, Appaiah H, Luktuke N, Carroll JS, Geistlinger TR, Brown M, Badve S, Liu Y, Nakshatri H: AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Mol Cell Biol. 2008, 28: 7487-7503. 10.1128/MCB.00799-08.CrossRefPubMedPubMedCentral Bhat-Nakshatri P, Wang G, Appaiah H, Luktuke N, Carroll JS, Geistlinger TR, Brown M, Badve S, Liu Y, Nakshatri H: AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Mol Cell Biol. 2008, 28: 7487-7503. 10.1128/MCB.00799-08.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R: Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010, 12: R40-10.1186/bcr2594.CrossRefPubMedPubMedCentral Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R: Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010, 12: R40-10.1186/bcr2594.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68: 826-833. 10.1158/0008-5472.CAN-07-2707.CrossRefPubMed Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68: 826-833. 10.1158/0008-5472.CAN-07-2707.CrossRefPubMed
15.
Zurück zum Zitat Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM: Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer. 2005, 12 (Suppl 1): S29-36. 10.1677/erc.1.00991.CrossRefPubMed Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM: Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer. 2005, 12 (Suppl 1): S29-36. 10.1677/erc.1.00991.CrossRefPubMed
Metadaten
Titel
More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response
verfasst von
Xiaoyong Fu
Catherine Huang
Rachel Schiff
Publikationsdatum
01.04.2011
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 2/2011
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2849

Weitere Artikel der Ausgabe 2/2011

Breast Cancer Research 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.